Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;7(10):e2439887.
doi: 10.1001/jamanetworkopen.2024.39887.

Characterizing GLP-1 Receptor Agonist Use in Preadolescent and Adolescent Populations

Margaret G Miller  1 , Pauline Terebuh  1 , David C Kaelber  2 , Rong Xu  1 , Pamela B Davis  3
Affiliations

Characterizing GLP-1 Receptor Agonist Use in Preadolescent and Adolescent Populations

Margaret G Miller et al. JAMA Netw Open. .
No abstract available

Plain language summary

This cross-sectional study examines the characteristics of preadolescent and adolescent populations who received glucagon-like peptide-1 (GLP-1) receptor agonists.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Terebuh reported receiving grants from National Institutes of Health during the conduct of the study. Dr Kaelber reported receiving grants from the National Center for Advancing Translational Sciences of the National Institutes of Health during the conduct of the study. No other disclosures were reported.

Figures

Figure.
Figure.. Overarching Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Prescriptions in Preadolescents and Adolescents
GLP-1RA usage following US Food and Drug Administration (FDA) approval for exenatide, liraglutide, and semaglutide. The left ordinate demonstrates the number of patients aged 10 to 17 years who were prescribed GLP-1RAs at TriNetX health care organizations (bars). The right ordinate indicates the number of patients aged 10 to 17 years with a diagnosis of type 2 diabetes or obesity in each year at TriNetX health care organizations (blue line).
See this image and copyright information in PMC

References

    1. Yan Y, Gong Y, Jiang M, et al. . Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study. Front Endocrinol (Lausanne). 2023;14:1170127. doi:10.3389/fendo.2023.1170127 - DOI - PMC - PubMed
    1. Lee JM, Sharifi M, Oshman L, Griauzde DH, Chua KP. Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023. JAMA. 2024;331(23):2041-2043. doi:10.1001/jama.2024.7112 - DOI - PMC - PubMed
    1. Alorfi NM, Alshehri FS. Usage of glucagon-like peptide-1 for obesity in children; updated review of clinicaltrials.gov. J Multidiscip Healthc. 2023;16:2179-2187. doi:10.2147/JMDH.S419245 - DOI - PMC - PubMed
    1. Hampl SE, Hassink SG, Skinner AC, et al. . Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640 - DOI - PubMed
    1. Guyton J, Jeon M, Brooks A. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. Am J Health Syst Pharm. 2019;76(21):1739-1748. doi:10.1093/ajhp/zxz179 - DOI - PubMed

Publication types

Substances